Aurobindo Pharma Q4 Net Profit Rises 2% on Growth in Europe and Other Markets
6 hours agoBusiness
30LENS
5 SourcesNew Delhi, India
TBNthebalanced.news

Aurobindo Pharma Q4 Net Profit Rises 2% on Growth in Europe and Other Markets

Aurobindo Pharma reported a 2 percent rise in consolidated net profit to around Rs 921 crore for Q4 FY26, supported by strong revenue growth in Europe and other growth markets despite a 13 percent decline in US formulations revenue. Total revenue increased about 5.6 percent to Rs 8,853 crore. For the full fiscal year, net profit was nearly flat at Rs 3,503 crore on a 6.1 percent revenue increase to Rs 33,653 crore. The company cited improved efficiencies and a diversified portfolio amid margin pressures.

Political Bias
0%100%0%
Sentiment
59%
AI analysis of 5 sources · Published under editorial oversight by The Balanced News
Analysed 22 May 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 5 sources
● Left 0%● Center 100%● Right 0%

The articles present a primarily business-focused perspective without evident political framing. Coverage centers on financial performance, market segments, and company statements, reflecting corporate and investor viewpoints. There is no partisan commentary or political analysis, maintaining a neutral economic lens across sources.

Sentiment — Neutral (59/100)

The overall tone is cautiously positive, highlighting modest profit growth and revenue gains alongside challenges like US market declines and margin pressures. The sentiment balances optimism from geographic diversification and operational improvements with acknowledgment of profitability constraints, resulting in a measured, business-oriented outlook.

How 5 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
businessstandardAurobindo Pharma share price plunges 7 as margins weigh on Q4 resultsCenterNeutral
businessstandardAurobindo Pharma consolidated net profit rises 1.97 in the March 2026 quarterCenterNeutral
moneycontrolAurobindo Pharma Q4 profit inches up 2 as Europe, growth markets offset US drag- Moneycontrol.comCenterNeutral
thehinduAurobindo Pharma Q4 net up 2 to 921 crCenterPositive
news18Aurobindo Pharma Q4 PAT edges up 2 pc at Rs 920.84 crCenterNeutral

Coverage timeline

news18 broke this story on 21 May, 03:53 pm. Other outlets followed.

  1. 1
    news1821 May, 03:53 pm
    Aurobindo Pharma Q4 PAT edges up 2 pc at Rs 920.84 cr
  2. 2
    thehindu21 May, 05:04 pm
    Aurobindo Pharma Q4 net up 2 to 921 cr
  3. 3
    moneycontrol21 May, 05:15 pm
    Aurobindo Pharma Q4 profit inches up 2 as Europe, growth markets offset US drag- Moneycontrol.com
  4. 4
    businessstandard22 May, 04:18 am
    Aurobindo Pharma consolidated net profit rises 1.97 in the March 2026 quarter
  5. 5
    businessstandard22 May, 09:09 am
    Aurobindo Pharma share price plunges 7 as margins weigh on Q4 results

Lens Score breakdown

30/100
Public interest0/100
Coverage gap100%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
Aurobindo Pharma LtdAurobindo Pharma

Story context

Category
Business
Location
New Delhi, India
Sources analysed
5
Last analysed
22 May 2026
Key entities
CroreIndian rupeeNet incomeEuropeAurobindo PharmaChief executive officerEuroActive ingredientChemical industryRevenueBusiness modelNew Delhi